James Whyte Black’s most consequential discoveries began with questions about how the body worked. By investigating the effects of adrenaline on the heart, he helped develop propranolol, a beta-blocker used to treat heart disease. Later, his work on histamine receptors led to cimetidine, a drug for peptic ulcers. These were not simply two successful medicines: Black’s career helped show how a detailed understanding of biological systems could guide the deliberate design of drugs.

A Scottish education and an early research career

Black was born in Uddingston, Lanarkshire, on 14 June 1924, the fourth of five sons in a Baptist family. He grew up in Fife and attended Beath High School in Cowdenbeath. His family could not afford to send him to university, but a mathematics teacher persuaded him to sit the entrance examination for the University of St Andrews. He won a scholarship at the age of 15.

He studied medicine at University College, Dundee, then part of the University of St Andrews, and graduated in 1946. Rather than become a medical practitioner, he stayed on as an assistant lecturer in physiology. He later took a teaching post in Singapore at the King Edward VII College of Medicine, which subsequently became part of the University of Malaya. After three years there, he moved to London and then joined the University of Glasgow’s veterinary school.

At Glasgow, Black established a veterinary physiology department and began investigating how adrenaline affects the human heart, particularly in people with angina. That research interest shaped the work that followed. He sought not merely to observe a drug’s effects, but to use an understanding of receptors and physiology to develop compounds for a defined therapeutic purpose.

Propranolol and the treatment of heart disease

Black joined ICI Pharmaceuticals in 1958 and remained there until 1964. During this period, his research produced propranolol, a beta-blocker that counteracts the effects of adrenaline at beta-adrenergic receptors. The drug opened new possibilities in the treatment of angina and other cardiovascular conditions, including cardiac irregularities and hypertension.

His approach was distinctive: rather than synthesising compounds first and then searching for possible uses, he worked from a planned theory of how a drug might act. Drug molecules were designed with a purpose, guided by receptor theory and the biological problem under investigation. Propranolol became a major treatment and helped establish this kind of rational drug development as an influential method in pharmacology.

Black’s work did not proceed without institutional obstacles. ICI was unwilling to pursue his ideas for a medicine to treat stomach ulcers. He left the company in 1964 and joined Smith, Kline and French, where he continued that line of research. The change of employer would lead to his second major drug discovery.

Cimetidine and a new approach to ulcers

At Smith, Kline and French, Black developed cimetidine, the first of a new class of medicines known as H2-receptor antagonists. It blocks a type of histamine receptor involved in gastric acid secretion. Marketed as Tagamet, cimetidine was launched in 1975 and became an important treatment for peptic ulcers.

The work extended the logic behind Black’s earlier research: identify a biological mechanism, then design a drug to act on it. Cimetidine’s significance lay both in its clinical use and in the evidence it provided for the role of histamine receptors in stomach acid secretion. Black’s work on propranolol and cimetidine thus connected practical treatments with a broader contribution to pharmacology and drug design.

Research, teaching and the University of Dundee

After leaving Smith, Kline and French in 1973, Black became professor and head of pharmacology at University College London. There he established an undergraduate course in medicinal chemistry. In 1978, he moved to the Wellcome Research Laboratories as director of therapeutic research, but resigned in 1984 after disagreements with his immediate superior.

He then became Professor of Analytical Pharmacology at King’s College London, remaining there until 1992. In 1988, with funding from Johnson & Johnson, he established the James Black Foundation and led a team of 25 scientists. Their work included research into gastrin inhibitors, which can prevent some stomach cancers.

Black’s association with Dundee resumed in 1992, when he became the university’s chancellor. He held the position until 2006 and used it to promote the institution. The university later named its Sir James Black Centre in his honour. Opened in 2006, the centre was intended to support interdisciplinary research in the life sciences. The recognition reflected a lasting connection: Dundee was where he had studied medicine, begun his university career and returned to serve as chancellor.

Honours and later life

Black shared the 1988 Nobel Prize in Physiology or Medicine with Gertrude B. Elion and George H. Hitchings. The award recognised their work on drug development and, in Black’s case, the research that led to propranolol and cimetidine. His other distinctions included election as a Fellow of the Royal Society in 1976, the Wolf Prize in Medicine in 1982 and the Royal Society’s Royal Medal in 2004. He was knighted in 1981 and appointed to the Order of Merit in 2000.

He married Hilary Joan Vaughan in 1946; they had a daughter. After her death, he married Professor Rona MacKie in 1994. Black died in London on 22 March 2010, aged 85. His Nobel medal had been donated to the National Museum of Scotland in 2009. Among the later commemorations of his work, the University of Glasgow renamed its West Medical Building in his honour in 2018.

Why James Black deserves a place in British Legacy

James Black’s place in British Legacy rests on more than the success of two medicines. Propranolol and cimetidine grew from a method of research that began with biological questions and used them to guide the deliberate design of drugs. His work on adrenaline and the heart helped create a new treatment for angina and other cardiovascular conditions. His later investigation of histamine receptors produced cimetidine, an important ulcer treatment, and helped clarify how gastric acid secretion could be controlled. These achievements joined advances in pharmacology to changes in clinical practice.

His career also connects research and education across British institutions. He studied and began his academic work in Dundee, established a physiology department in Glasgow, taught and led research at University College London and King’s College London, and returned to Dundee as chancellor. The Sir James Black Centre gives that connection a continuing institutional form, with its focus on interdisciplinary life-sciences research. His Nobel recognition and honours acknowledge the reach of his discoveries; the more specific legacy is the research strategy he advanced and the scientific institutions in which he worked. Black’s British contribution is therefore not a general claim about national ingenuity, but a record of particular discoveries, teaching and university service that influenced medicine well beyond Britain.

Sources

James Black (pharmacologist), revision 1376551293

Adapted in part from James Black (pharmacologist) by Wikipedia contributors, under CC BY-SA 4.0. Text has been edited and combined with the existing article; this adapted text is shared under the same licence. Contributor history.